News | January 11, 2026
Johnson & Johnson strikes deal With Trump admn to cut drug costs, expand manufacturing
The agreement responds directly to President Trump’s demands that drugmakers cut costs for US patients
The agreement responds directly to President Trump’s demands that drugmakers cut costs for US patients
The decision follows an interim analysis conducted when roughly half of the patients had completed their Day 84 visit
KRAS G12C-mutant advanced or metastatic nonsquamous non-small cell lung cancer
Collaboration funds participating biotechs to access Lilly predictive models through the Revvity Signals Xynthetica offering
Phase 3 study met all primary and secondary endpoints, demonstrating superior convenience, strong efficacy, and excellent safety versus conventional ondansetron injections
The new facility offers an expanded laboratory alongside meeting areas dedicated to development meetings, formulation workshops, and brainstorming sessions
The FDA designation follows visual-function results from the Phase 2 ACUITY trial
This is the first controlled pharmacologic study to demonstrate that treatment of obesity improved PsA disease measures
The trial aims to measure AF burden—the percentage of time patients spend in arrhythmia—as its primary efficacy endpoint
Blood tests measuring biomarkers such as p-tau217 are emerging as accurate, accessible alternatives
Subscribe To Our Newsletter & Stay Updated
